Niche therapeutic focus AiViva Biopharma concentrates on localized, targeted treatments to reduce systemic exposure in Dermatology, Ophthalmology, Urology, and Oncology, highlighting cross‑sales opportunities with specialty pharma, contract research organizations, and clinics focusing on unmet medical needs.

JEL technology leverage The proprietary JEL platform positions AiViva to collaborate on drug delivery improvements and combination therapies; explore licensing, co‑development, or integration deals with biotech firms seeking enhanced formulation and targeted delivery capabilities.

Clinical stage pipeline With programs like AIV007 and AIV001 advancing from early phases, there is a sales window for CROs, investigators, and patient recruitment networks to engage in trials, site partnerships, and investigator sponsorships to accelerate development.

Global-scale growth signals Recent board appointment and a growing diverse product pipeline indicate readiness for strategic partnerships, potential capital raises, and international expansion; engage investors, strategic alliances, and potential acquirers seeking biotech footholds.

Financial and scale gap Revenue is modest relative to large peers and funding appears limited; target cost‑effective partnerships, co‑development agreements, and service offerings (clinical operations, regulatory support, manufacturing optimization) to monetize AiViva’s niche capabilities.